Novo Nordisk A/S

24 ago 2026

• SeekingAlpha09:00
  Novo Nordisk: Don't Ignore This Dirt-Cheap Buying Opportunity

  Novo Nordisk (NVO) may be bottoming as LLY share losses stabilize; trading ~15x forward earnings with catalysts like Wegovy pill & CagriSema.

22 ago 2026

• SeekingAlpha10:51
  Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk

  Eli Lilly (LLY) leads the global obesity drug market vs Novo Nordisk as competition heats up.

21 ago 2026

• SeekingAlpha18:50
  Novo Nordisk: The Pill That Could Close The Gap With Lilly

  Novo Nordisk A/S stays a Buy as oral Wegovy surges and GLP-1 pipeline strengthens; attractive 2028 P/E suggests upside—click to read the NVO stock outlook now.

19 ago 2026

• SeekingAlpha14:07
  Novo Nordisk: The Best Value In Pharma
• Benzinga09:09
  'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ

  https://www.wsj.com/health/pharma/novo-nordisk-starts-testing-lower-doses-of-its-wegovy-weight-loss-pills-8896fec2

12 ago 2026

• SeekingAlpha10:02
  The Market Is (Still) Underestimating Novo Nordisk

11 ago 2026

• Benzinga08:07
  Novo Nordisk Announces U.S. Availability Of Awiqli, Its First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes

  Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing frequency of these weekly basal injections from seven to one per week1Awiqli® will be available at over 70,000

7 ago 2026

• SeekingAlpha14:30
  Reassessing Inflammation's Link To Cardiovascular Risk

  There have been some puzzling results in connecting inflammation with cardiovascular disease, but Novo Nordisk's recent trial result is by far the biggest hit the hypothesis has ever taken.

• SeekingAlpha10:55
  Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade

  Novo Nordisk A/S gets a Sell rating as profits slide, guidance weakens, and competition rises vs Eli Lilly. Click for this NVO stock update and a look at earnings.

6 ago 2026

• SeekingAlpha12:33
  Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore

  Novo Nordisk A/S beat Q2 revenue and EPS, raised guidance again, and still dipped. Click for this NVO stock update and see if it is right for you.

• Benzinga10:06
  Novo Nordisk Scores Major Court Win, Dutch Judge Halts Compounded Semaglutide Nasal Spray

  A Dutch court has banned sales of an unapproved compounded semaglutide nasal spray following a legal victory for Novo Nordisk.

5 ago 2026

• SeekingAlpha14:10
  Novo Nordisk A/S (NOVO:CA) Q2 2026 Earnings Call Transcript

  Novo Nordisk A/S (NOVO:CA) Q2 2026 Earnings Call August 5, 2026 7:00 AM EDTCompany ParticipantsMichael Novod - Senior VP & Head of Investor...

• SeekingAlpha12:04
  Novo Nordisk A/S 2026 Q2 - Results - Earnings Call Presentation

  2026-08-05. The following slide deck was published by Novo Nordisk A/S in conjunction with their 2026 Q2 earnings call.

• SeekingAlpha11:36
  Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)

  Novo Nordisk Q2 results: obesity drug growth (Wegovy pill) offsets pricing pressure. Shares fell 6%, but DCF suggests 25% upside. Click for more on NVO stock.

4 ago 2026

• Benzinga18:03
  Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

  Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.81 by 18.52 percent. This is a 5.49 percent increase over earnings of $0.91 per share from the same

• Benzinga14:38
  Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

  Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.

• Benzinga12:46
  Novo Nordisk Reports DKK 6.3B Non-Recurring, Non-Cash Impairment Charges In Q2 Related To Intangible Pipeline Assets

  https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916590